Related references
Note: Only part of the references are listed.SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma
Rene -Olivier Casasnovas et al.
BLOOD (2011)
Midtreatment 18F-Fluorodeoxyglucose Positron-Emission Tomography in Aggressive Non-Hodgkin Lymphoma
Pier Luigi Zinzani et al.
CANCER (2011)
Role of Functional Imaging in the Management of Lymphoma
Bruce D. Cheson
JOURNAL OF CLINICAL ONCOLOGY (2011)
Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study
Sandra J. Horning et al.
BLOOD (2010)
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
Bertrand Coiffier et al.
BLOOD (2010)
Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma
Craig H. Moskowitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
Christian Gisselbrecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Mechanisms of Disease: Aggressive Lymphomas.
Georg Lenz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens
H. S. Han et al.
ANNALS OF ONCOLOGY (2009)
Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study
Umberto Vitolo et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for Interim Response Assessment of Advanced-Stage Hodgkin's Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review
Teruhiko Terasawa et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The Case Against Heavy PETing
Bruce Cheson
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy
Emmanuel Itti et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
PET/CT for Therapy Response Assessment in Lymphoma
Martin Hutchings et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Interim F-18-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation - where do we stand?
Michel Meignan et al.
LEUKEMIA & LYMPHOMA (2009)
Report on the First International Workshop on interim-PET scan in lymphoma
Michel Meignan et al.
LEUKEMIA & LYMPHOMA (2009)
R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study
Alejandro Martin et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas:: a randomised controlled trial (RICOVER-60)
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2008)
False positive PET scanning caused by inactivated influenza virus vaccination during complete remission from anaplastic T-cell lymphoma
Daniele Focosi et al.
ANNALS OF HEMATOLOGY (2008)
Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma:: SUV-based assessment versus visual analysis
Chieh Lin et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
False-positive FDG-PET findings clue to bone metastasis from prostate cancer in staging of non-Hodgkin's lymphoma
Yuko Inoue et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2007)
High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - Results of a comprehensive meta-analysis
Alexander Greb et al.
CANCER TREATMENT REVIEWS (2007)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in lymphoma
Malik E. Juweid et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease
Lale Kostakoglu et al.
CANCER (2006)
False-positive restaging PET scans involving the spleen in two patients with aggressive non-Hodgkin lymphoma
Clyde D. Ford et al.
CLINICAL NUCLEAR MEDICINE (2006)
[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma:: an early prognostic tool for predicting patient outcome
C Haioun et al.
BLOOD (2005)
Response assessment of aggressive non-Hodgkin's lymphoma by integrated international workshop criteria and fluorine-18-fluorodeoxyglucose positron emission tomography
ME Juweid et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma
K Spaepen et al.
ANNALS OF ONCOLOGY (2002)
Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer
M Colleoni et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
